While interesting, this report provides little insight into possible reasons for an observed increase in treatment-associated acute myeloid leukemia. As the authors point out, t-AML has declined in patients treated for ovarian cancer, likely due to a change in the standard chemotherapy used. For non-Hodgkin’s lymphoma, one would like to know if there has been a similar change in treatment, in the opposite direction, that accounts for an increase in t-AML. Is there a greater use of transplant, which is known to be associated with t-AML? Have these patients been treated more intensively with alkylator-based regimens?
Dr. Steven Coutré is associate professor, division of hematology, and director of the hematology clinic at Stanford (Calif.) University. He had no disclosures.
FROM BLOOD
Dr. Coutré is associate professor, division of hematology, and director of the hematology clinic at Stanford (Calif.) University. He had no disclosures.
